Trials / Withdrawn
WithdrawnNCT01650467
Imatinib Response in Patients With Chronic Myeloid Leukemia (CML) in Function of Abl Polymorphisms
- Status
- Withdrawn
- Phase
- —
- Study type
- Observational
- Enrollment
- 0 (actual)
- Sponsor
- Centre Hospitalier Universitaire de Nīmes · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The main objective of this study is to evaluate the existence of a relationship between the presence of certain abl polymorphisms (or haplotypes) upon CML diagnosis and the occurrence of primary resistance to the treatment of CML by imatinib.
Detailed description
The first secondary objective of this study is to identify, in patients not responding to treatment, possible changes in the polymorphisms of interest during the course of the disease, reclassifying such polymorphisms as mutations. The second secondary objective is to compare the control patients in terms of polymorphism frequency on the nonpathological abl fraction.
Conditions
Timeline
- Start date
- 2014-12-01
- Primary completion
- 2017-06-01
- Completion
- 2017-06-01
- First posted
- 2012-07-26
- Last updated
- 2017-02-01
Locations
3 sites across 1 country: France
Source: ClinicalTrials.gov record NCT01650467. Inclusion in this directory is not an endorsement.